GSK cements Blenrep comeback with MHRA approval

GSK cements Blenrep comeback with MHRA approval

GSK cements Blenrep comeback with MHRA approval Jonah.Comstock Fri, 18/04/2025 - 15:31 Bookmark this

GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring requirements for Camzyos.

GSK blood cancer therapy, once pulled from the market, is approved in the U.K.

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K. on Thursday, marking the medicine’s return to the market after it was withdrawn several years ago. The drug, which treats multiple myeloma, will be used in combination with other medicines in patients whose cancer has resurged after an earlier line of treatment, under the approval from the Medicines and Healthcare products Regulatory Agency. Blenrep had previously been approved …

Blenrep combos approved in UK as multiple myeloma treatment

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Blenrep (belantamab mafodotin) in combination with other medications for hard-to-treat multiple myeloma. The MHRA approved Blenrep in combination with Velcade (bortezomib) and dexamethasone for people with myeloma who have received at least one prior line of therapy, and Blenrep plus Pomalyst (pomalidomide) and dexamethasone (PomDex) in patients who’ve had one pri…

Belantamab Mafodotin–Based Combos Win UK Approval for R/R Myeloma

Two belantamab mafodotin–based combinations have been approved in the United Kingdom for relapsed/refractory multiple myeloma.

GSK kicks off Blenrep relaunch plans with clearance from UK regulators

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the drug’s first approval worldwide since it was pulled from the US and other global markets. ...